Canine Atopic Dermatitis Welfare: Itch Control and Biologic Therapy in 2026

Canine atopic dermatitis is a chronic, intensely pruritic skin condition affecting approximately 10-15% of dogs. By 2026, biologic therapies including lokivetmab (Cytopoint) and oclacitinib (Apoquel) have transformed welfare outcomes, providing sustained itch relief without the side effects of long-term steroid use.

Key Facts

Atopic dermatitis affects 10-15% of dogs, with West Highland terriers, Labrador retrievers, and French bulldogs at highest risk
The condition causes chronic pruritus — persistent itch — that severely disrupts sleep, social behaviour, and quality of life
Lokivetmab (Cytopoint) is a monoclonal antibody blocking IL-31, providing 4-8 weeks of itch relief per injection
Oclacitinib (Apoquel) blocks JAK1 to reduce itch and inflammation with rapid onset within 4 hours
Secondary bacterial and yeast infections from skin barrier disruption are a major compounding welfare problem

Welfare Considerations

Atopic dogs scratch, lick, bite, and rub affected areas compulsively — behaviour that disrupts sleep, causes self-trauma, and creates chronic cycles of secondary infection. Dogs that cannot sleep due to pruritus show progressive behavioural and physical deterioration. Pre-biologic management relied on long-term steroids with associated diabetes, Cushing's syndrome, and immune suppression risks. Cytopoint and Apoquel have transformed management: targeted itch relief without systemic immune suppression provides sustained welfare improvement with an excellent safety profile. Welfare assessment should include validated pruritus scoring tools (PVAS) and owner quality-of-life questionnaires to objectively track treatment response.

What You Can Do

Consult a veterinary dermatologist for atopic dermatitis management — specialist diagnosis improves treatment precision
Discuss Cytopoint or Apoquel as first-line itch management alternatives to long-term steroids
Use validated pruritus scoring tools to objectively track treatment response and guide dosing
Address secondary bacterial and yeast infections promptly — uncontrolled infection dramatically worsens itch
Support veterinary dermatology research through donations to RCVS Knowledge and veterinary school foundations